Skip to content

Efficacy of Tadalafil on improvement of erectile dysfunction

Efficacy of Tadalafil on improvement of erectile dysfunction caused by Covid 19

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170807035551N2
Enrollment
60
Registered
2021-01-16
Start date
2021-01-20
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction. Male erectile dysfunction

Interventions

Intervention 1: Intervention group: Prescribing Tadalafil 10 mg tablets from Rouzdarou company daily 1 tablet after lunch for 2 months.(A total of 60 capsules, each containing a 10 mg tablet of Tadala

Sponsors

Urology Research Center of Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
30 Years to 50 Years

Inclusion criteria

Inclusion criteria: Erectile dysfunction after recovery from C0VID19 Men between the ages of 30 and 50 Obtaining patient consent

Exclusion criteria

Exclusion criteria: History of erectile dysfunction before COVID19 History of trauma or anatomical problems in the penis A history of neurological disorders including spinal cord injury, stroke, and migraine History of heart disease History of taking mineral nitrate drugs

Design outcomes

Primary

MeasureTime frame
Measuring the severity of erectile dysfunction. Timepoint: before intervention, two months after intervention. Method of measurement: International index of erectile function questionnaire.;Sexual satisfaction of patient. Timepoint: before intervention, two months after intervention. Method of measurement: International index of erectile function questionnaire.;Intensity of sexual desire. Timepoint: before intervention, two months after intervention. Method of measurement: International index of erectile function questionnaire.

Secondary

MeasureTime frame
Complications of drug administration. Timepoint: During the intervention and two months after the start of the intervention. Method of measurement: Based on questions from the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactIman Shamohammadi

Tehran University of Medical Sciences

shariatihosp@tums.ac.ir+98 21 8490 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026